AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research

被引：0
|
作者：
Lei-Lei Wu
Wen-Mei Jiang
Zhi-Yuan Liu
Yi-Yi Zhang
Jia-Yi Qian
Yu’e Liu
Yang-Yu Huang
Kun Li
Zhi-Xin Li
Guo-Wei Ma
Dong Xie
机构：
[1] Tongji University,Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine
[2] Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
[3] Tongji University,School of Medicine
[4] The University of Manchester,Faculty of Biology, Medicine and Health, School of Biological Sciences
来源：
Discover Oncology | / 14卷
关键词：
KRAS G12C mutation; AMG-510; Cisplatin; In vivo; Translational medicine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] KRAS-G12C Mutation is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma Response
    Nadal, Ernest
    Beer, David G.
    Ramnath, Nithya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : E9 - E10
  • [42] Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
    Desai, Jayesh
    Han, Sae-Won
    Lee, Jong-Seok
    Shacham-Shmueli, Einat
    Massarelli, Erminia
    Cervantes, Andres
    Garralda, Elena
    Falcon, Alejandro
    Miller, Wilson H.
    Gort, Eelke
    Karasic, Thomas
    Siena, Salvatore
    Stec, Rafal
    Medina, Laura
    Paz-Arez, Luis
    Delmonte, Angelo
    Sacher, Adrian
    Prenen, Hans
    Forster, Martin
    Kim, Tae Won
    Krebs, Matthew G.
    Cosman, Rasha
    Choi, Yoonha
    Mandlekar, Sandhya
    Lin, Mark T.
    Yau, Kenneth K.
    Chang, Julie
    Royer-Joo, Stephanie
    Dharia, Neekesh V.
    Schutzman, Jennifer L.
    Patel, Manish
    CANCER RESEARCH, 2023, 83 (08)
  • [43] TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemo-immunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma
    Di Federico, Alessandro
    Hong, Lingzhi
    Elkrief, Arielle
    Thummalapalli, Rohit
    Cooper, Alissa Jamie
    Shaverdian, Narek
    Ricciuti, Biagio
    Alessi, Joao Victor Machado
    De Giglio, Andrea
    Pecci, Federica
    Lamberti, Giuseppe
    Gandhi, Malini Marion
    Sholl, Lynette M.
    Nishino, Mizuki
    Ardizzoni, Andrea
    Heist, Rebecca Suk
    Arbour, Kathryn C.
    Schoenfeld, Adam Jacob
    Vokes, Natalie I.
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
    Spira, A.
    Riely, G.
    Lawler, W.
    Shum, M.
    Socinski, M.
    Yanagihara, R.
    Roshan, S.
    Kheoh, T.
    Christensen, J.
    Chao, R.
    Janne, P.
    Garassino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S695 - S696
  • [45] The Use of Lung Adenocarcinoma Patient-Derived Xenografts and Organoids to Study GDP-KRAS G12C Inhibitor Resistance
    Rosen, J.
    Sacher, A.
    Pham, N. -A.
    Weiss, J.
    Li, Q.
    Koga, T.
    Tucker, S.
    Radulovich, N.
    Koers, A.
    Niedbala, M.
    Ross, S.
    Tsao, M. -S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S437 - S438
  • [46] PHASE 2 STUDY OF THE GI-4000 KRAS VACCINE FOLLOWING CURATIVE THERAPY IN PATIENTS WITH STAGE I-III LUNG ADENOCARCINOMA HARBORING A KRAS G12C, G12D, G12V OR G12R MUTATION
    Chaft, Jamie E.
    Arcila, Maria
    Patel, Payal
    Apelian, David M.
    Mattson, Alicia
    Coeshott, Claire
    Kris, Mark G.
    Azzoli, Christopher G.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S302 - S302
  • [47] Characteristics and treatment outcomes in advanced stage non-small cell lung cancer patients with KRAS G12C mutation
    Illini, Oliver
    Fabikan, Hannah
    Hochmair, Maximilian J.
    Weinlinger, Christoph
    Krenbek, Dagmar
    Brcic, Luka
    Setinek, Ulrike
    Terbuch, Angelika
    Absenger, Gudrun
    Konji, Selma
    Valipour, Arschang
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (19-20) : 727 - 728
  • [48] Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
    Si-Yang Liu
    Hao Sun
    Jia-Ying Zhou
    Guang-Ling Jie
    Zhi Xie
    Yang Shao
    Xian Zhang
    Jun-Yi Ye
    Chun-Xiang Chen
    Xu-Chao Zhang
    Qing Zhou
    Jin-Ji Yang
    Yi-Long Wu
    Biomarker Research, 8
  • [49] Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model
    King, Peter J.
    Axel, Amy E.
    Fowler, Kevin D.
    Kolitz, Sarah E.
    Barrett, Scott
    Zeskind, Benjamin J.
    Hall, Brett M.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [50] AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial
    Strickler, J. H.
    Fakih, M.
    Price, T. J.
    Desai, J.
    Durm, G.
    Krauss, J. C.
    Kuboki, Y.
    Kim, T. W.
    Sacher, A.
    Henary, H.
    Kim, J.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1274 - S1275
12345